Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery
Status:
Recruiting
Trial end date:
2026-05-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well osimertinib works in treating participants with stage
I-IIIA Epithelial Growth Factor Receptor (EGFR) -mutant non-small cell lung cancer before
surgery. Osimertinib may stop the growth of tumor cells by blocking mutant EGFR signaling in
cancer cells.